Your browser is no longer supported. Please, upgrade your browser.
Settings
CBIO Catalyst Biosciences, Inc. daily Stock Chart
CBIO [NASD]
Catalyst Biosciences, Inc.
Index- P/E- EPS (ttm)-4.37 Insider Own0.30% Shs Outstand16.06M Perf Week8.92%
Market Cap113.70M Forward P/E- EPS next Y-3.30 Insider Trans0.00% Shs Float15.70M Perf Month-1.53%
Income-52.40M PEG- EPS next Q-0.39 Inst Own51.80% Short Float3.98% Perf Quarter36.94%
Sales0.00M P/S- EPS this Y64.00% Inst Trans1.33% Short Ratio1.00 Perf Half Y-2.61%
Book/sh6.76 P/B1.05 EPS next Y8.30% ROA-44.10% Target Price24.75 Perf Year-15.51%
Cash/sh5.29 P/C1.34 EPS next 5Y- ROE-47.40% 52W Range4.52 - 10.84 Perf YTD3.96%
Dividend- P/FCF- EPS past 5Y63.40% ROI- 52W High-34.69% Beta2.00
Dividend %- Quick Ratio9.80 Sales past 5Y- Gross Margin- 52W Low56.64% ATR0.53
Employees21 Current Ratio9.80 Sales Q/Q- Oper. Margin- RSI (14)47.94 Volatility5.84% 7.09%
OptionableYes Debt/Eq0.00 EPS Q/Q-64.00% Profit Margin- Rel Volume1.32 Prev Close6.83
ShortableYes LT Debt/Eq0.00 EarningsMar 05 BMO Payout- Avg Volume622.33K Price7.08
Recom1.70 SMA20-2.10% SMA504.81% SMA2004.33% Volume804,738 Change3.66%
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Jun-30-16Initiated Rodman & Renshaw Buy $3.50
Feb-24-20 08:00AM  Catalyst Biosciences to Present at the Cowen Healthcare Conference GlobeNewswire
Feb-20-20 04:05PM  Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Feb-18-20 04:05PM  Catalyst Biosciences Announces Closing of Public Offering of Common Stock GlobeNewswire
Feb-13-20 09:15AM  Catalyst Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire -18.65%
Feb-12-20 04:15PM  Catalyst Biosciences Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-07-20 07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga +13.16%
03:30AM  Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress GlobeNewswire
Jan-27-20 08:00AM  Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress GlobeNewswire
Jan-17-20 08:00AM  Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors GlobeNewswire
Dec-30-19 01:12PM  Imagine Owning Catalyst Biosciences (NASDAQ:CBIO) And Wondering If The 31% Share Price Slide Is Justified Simply Wall St.
Dec-20-19 11:10AM  Company News For Dec 20, 2019 Zacks -6.32%
Dec-19-19 09:34PM  Catalyst Biosciences Inc (CBIO): Hedge Fund Sentiment Unchanged But Bullish Insider Monkey +65.83%
11:44AM  Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 19, 2019: NKE, TIVO, CBIO, APOG, RAD Benzinga
08:00AM  Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration GlobeNewswire
Dec-09-19 08:00AM  Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference GlobeNewswire
Nov-12-19 08:00AM  Catalyst Biosciences to Present at the Stifel Healthcare Conference GlobeNewswire -6.42%
Nov-07-19 08:00AM  Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Nov-06-19 08:00AM  Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference GlobeNewswire
Oct-31-19 08:04AM  We're Keeping An Eye On Catalyst Biosciences's (NASDAQ:CBIO) Cash Burn Rate Simply Wall St.
Oct-04-19 10:08AM  Company News For Oct 4, 2019 Zacks -6.96%
Oct-03-19 08:00AM  Catalyst Biosciences Provides DalcA Phase 2b Trial Update GlobeNewswire +24.60%
Oct-02-19 09:00AM  22NW: Catalyst Biosciences Needs Change Now PR Newswire +9.73%
Sep-30-19 11:18AM  Catalyst Biosciences Enters Oversold Territory Zacks -5.21%
Sep-27-19 09:00AM  22NW: Catalyst Biosciences Needs Change Now PR Newswire
Sep-26-19 08:00AM  Catalyst Biosciences to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-25-19 11:14AM  Are Insiders Selling Catalyst Biosciences, Inc. (NASDAQ:CBIO) Stock? Simply Wall St.
Aug-29-19 04:55PM  Catalyst Biosciences Announces Transition of Chief Financial Officer GlobeNewswire
Aug-20-19 01:49PM  How Should Investors Feel About Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Pay? Simply Wall St.
Aug-16-19 08:03AM  Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit GlobeNewswire
Aug-08-19 08:00AM  Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15 GlobeNewswire
Aug-01-19 08:00AM  Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update GlobeNewswire +6.72%
Jul-26-19 08:00PM  Round Robin, Hertz, Catalyst Biosciences and Other 13D Filings Barrons.com
Jul-08-19 01:50PM  A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019 Benzinga -11.39%
05:00AM  Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors GlobeNewswire
Jul-02-19 11:53AM  If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You'd Be Sitting On A 68% Loss, Today Simply Wall St. +6.20%
Jul-01-19 08:00AM  Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis GlobeNewswire
May-28-19 08:00AM  Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-02-19 08:00AM  Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update GlobeNewswire -5.31%
Apr-29-19 08:05AM  Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration GlobeNewswire +6.92%
Apr-03-19 08:00AM  Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference GlobeNewswire
Apr-02-19 08:00AM  Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B GlobeNewswire
Apr-01-19 02:33PM  Could The Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ownership Structure Tell Us Something Useful? Simply Wall St. +10.11%
12:45PM  Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated) GlobeNewswire
Mar-08-19 09:48PM  Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-07-19 08:00AM  Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Mar-06-19 08:00AM  Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting GlobeNewswire
Feb-19-19 08:10AM  New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-08-19 08:00AM  Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress GlobeNewswire
Feb-06-19 08:00AM  Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B GlobeNewswire -6.79%
Feb-05-19 08:00AM  Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference GlobeNewswire
Jan-31-19 08:30AM  Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders GlobeNewswire
Jan-22-19 02:21PM  Is Catalyst Biosciences, Inc.s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future? Simply Wall St.
Jan-09-19 08:36AM  Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll Zacks
Jan-08-19 07:20AM  These 5 Stocks Make Great Buys on New Analyst Coverage Zacks
Dec-18-18 12:00PM  Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs GlobeNewswire
Dec-10-18 08:00AM  Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs GlobeNewswire
Dec-01-18 12:00PM  Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors GlobeNewswire
Nov-21-18 11:56AM  What Did Catalyst Biosciences Incs (NASDAQ:CBIO) CEO Take Home Last Year? Simply Wall St.
Nov-02-18 08:00AM  Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition GlobeNewswire +9.26%
Nov-01-18 08:00AM  Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update GlobeNewswire +11.57%
Oct-25-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within StoneMor Partners, Catalyst Biosciences, Kennametal, Emergent Biosolutions, Kimball International, and Tailored Brands New Research Emphasizes Economic Growth GlobeNewswire
Oct-24-18 08:00AM  Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides GlobeNewswire
Sep-25-18 08:00AM  Catalyst Biosciences to Present at Two Upcoming Healthcare Investor Conferences GlobeNewswire
Sep-18-18 11:15AM  How Does Catalyst Biosciences Inc (NASDAQ:CBIO)s Prospect Stack Up To Its Healthcare Peers? Simply Wall St.
Sep-05-18 08:30AM  Market Trends Toward New Normal in Shutterstock, CrossAmerica Partners LP, Allegiance Bancshares, Portola Pharmaceuticals, StoneMor Partners, and Catalyst Biosciences Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-04-18 08:00AM  Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis GlobeNewswire
Aug-30-18 08:00AM  Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference GlobeNewswire
Aug-15-18 08:30AM  Report: Developing Opportunities within The Providence Service, NVE, StoneMor Partners, Midland States, Destination XL Group, and Catalyst Biosciences Future Expectations, Projections Moving into 2018 GlobeNewswire
08:00AM  Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit GlobeNewswire
Aug-13-18 08:00AM  Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit GlobeNewswire
Aug-02-18 08:00AM  Catalyst Biosciences Reports Second Quarter Operating & Financial Results and Provides Corporate Update GlobeNewswire +6.55%
Aug-01-18 06:58AM  Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS Zacks
04:04AM  Catalyst Biosciences (CBIO) Enters Oversold Territory Zacks
Jul-31-18 01:35PM  5 Top-Ranked Stocks to Benefit From Rising P/E Investing InvestorPlace
08:22AM  5 Top-Ranked Stocks to Benefit From Rising P/E Investing Zacks
Jul-23-18 12:06PM  After the Latest Plunge, Catalyst Stock Just Might Be Worth Buying InvestorPlace
Jul-18-18 10:41AM  Catalyst Biosciences Shares Volatile On Positive Late-Stage Hemophilia Trial Results Benzinga
07:18AM  Catalyst Biosciences shares surge 23% on positive results for one patient in late-stage hemophilia trial MarketWatch
07:00AM  Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors GlobeNewswire
Jul-12-18 08:00AM  Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis GlobeNewswire
Jul-10-18 08:00AM  Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research GlobeNewswire
Jun-25-18 08:30AM  Catalyst Biosciences Joins the Russell 2000® Index GlobeNewswire
Jun-19-18 10:25AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Biosciences, Inc. (CBIO) ACCESSWIRE +14.82%
08:36AM  Implied Volatility Surging for Catalyst Biosciences (CBIO) Stock Options Zacks
08:10AM  Todays Research Reports on Stocks to Watch: PTC Therapeutics and Catalyst Biosciences ACCESSWIRE
08:00AM  Catalyst Biosciences to Present at the JMP Securities 2018 Life Sciences Conference GlobeNewswire
Jun-18-18 03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Biosciences, Inc. - CBIO PR Newswire -63.92%
01:33PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Biosciences, Inc. (CBIO) PR Newswire
06:30AM  Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B GlobeNewswire
May-23-18 08:30AM  New Research Coverage Highlights BlackRock Capital Investment, Tootsie Roll Industries, Catalyst Biosciences, Macerich, Quotient Technology, and PennyMac Mortgage Investment Trust Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-09-18 06:07PM  Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with Inhibitors GlobeNewswire
May-03-18 08:00AM  Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update GlobeNewswire
Apr-23-18 08:00AM  Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting GlobeNewswire
Apr-12-18 08:00AM  Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B GlobeNewswire
Mar-30-18 08:30AM  Analysis: Positioning to Benefit within Catalyst Biosciences, CorEnergy Infrastructure Trust, PennyMac Mortgage Investment Trust, Raven Industries, Acacia Communications, and Sandy Spring Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-26-18 08:00AM  Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset GlobeNewswire
Mar-19-18 08:00AM  Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference GlobeNewswire
Mar-09-18 07:40AM  Zacks.com featured highlights include: Unisys, Catalyst, Liberty and New Mountain Zacks
Mar-07-18 08:00AM  Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-05-18 04:01PM  Catalyst Biosciences Announces the Calling of Remaining Warrants and Conversion of Remaining Series A Preferred Shares Issued April 12, 2017 GlobeNewswire +11.73%
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase 2 development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation subcutaneously-administered factor IX (FIX) therapy that is in Phase 2b clinical trials for the treatment of hemophilia B. The company's products also comprise CB 2679d-GT, a FIX gene therapy construct; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (dry AMD); and CB 1965a, a Factor Xa procoagulant molecule. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Richard John PDirectorMay 24Buy8.031,0008,0301,216May 28 09:45 AM
Levy HowardChief Medical OfficerMay 21Option Exercise4.634,40020,37216,094May 22 12:23 PM
USMAN NASSIMPresident & CEOMay 21Option Exercise4.634,40020,37210,567May 22 02:17 PM